Adolescent Medicine

Alcohol Abuse

Allergies and Infant Formula

Allergy, Immunology, and ENT

Animal Allergies

Autism

COVID-19

Cardiovascular Diseases

Cardiology

Atopic Dermatitis

Acne

Dermatology

Developmental/Behavioral Disorders

Diabetes

Drug Pipeline News

Emergency Medicine

Diabetes Type 2

Endocrinology

Gastroenterology

Gynecology

Antibiotic Resistance

Vaccination and Immunization

Bacterial Conjunctivitis

Vaccines

Infectious disease

Influenza

Anxiety

Depression

Mental Health

Concussion

Epilepsy

Headache

Neurology

Food Allergies

Obesity

Childhood Obesity

Nutrition

Nutrition News

Neonatal/Perinatology

Obstetrics-Gynecology & Women's Health

Oncology

Pain

Pharmacology

Practice Improvement

ADHD

Antisocial Personality Disorder

Psychiatry

Asthma

Cystic Fibrosis

Pediatric Asthma

Pneumonia

Respiratory

Rheumatoid Arthritis

Sexually Transmitted Diseases

Sexual Health

Skin Diseases

Telemedicine

News 

All News

PNP Corner

AAP Guidelines

Media

Around the Practice

Cure Connections

Expert Interviews

Insights

Medical World News

Peer Exchange

Peers & Perspectives

Podcasts

Webinars

Puzzler

Publications

Contemporary Pediatrics Journal

Supplements And Featured Publications

CME/CE

Resources

Handouts

Job Board

Conferences

Conference Coverage

Conference Listing

Partnerships

Subscribe

Print Subscription

eNewsletter

Editorial

Editorial Advisory Board

Writer’s Guidelines

Reference Guidelines

Meet the Editors

Joshua Fitch is an editor for Contemporary Pediatrics. 

Articles

The FDA has accepted a supplemental New Drug Application (sNDA) for roflumilast cream 0.15% for the treatment of atopic dermatitis (AD) in children aged 6 years and up. 

FDA accepts sNDA for roflumilast cream 0.15% to treat atopic dermatitis

Yamo Pharmaceuticals has initiated a phase 3 readiness program for L1-79, following the enrollment of its final patient in a phase 2 study evaluating the autism spectrum disorder (ASD) treatment for patients aged 2 to 21 years. 

Yamo enrolls final patient of phase 2 study of L1-79 to treat symptoms of ASD

The FDA granted Priority Review to pz-cel following a phase 1/2 and a pivotal phase 3 study in which the treatment for recessive dystrophic epidermolysis bullosa (RDEB) demonstrated wound healing and pain reduction. 

Pz-cel granted FDA Priority Review to treat recessive dystrophic epidermolysis bullosa

The 2022-2023 influenza season was the fourth season to be classified as high severity since the 2009 influenza A(H1N1) pandemic. 

2022-2023 influenza season classified as high severity

About Us

Advertise

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Contemporary Pediatrics

Facebook

Twitter

LinkedIn

Instagram

Spotlight

2022 Best Tech

Changing Landscape in RSV Prevention

Food Insecurity and the Dangers of Infant Formula Dilution

Opt-Out Chlamydia Screening in Adolescent Care

Pediatric ADHD: Zeroing in on an Untenable Burden

The Role of the Healthcare Provider Community in Increasing Public Awareness of RSV in All Infants

Chokechai Rongkavilit, MD

Articles